Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand
Count Flagship Pioneering in for the long and convoluted chase of new delivery vehicles that promise to expand the booming gene therapy field.
Ring Therapeutics, its latest biotech creation, has a $50 million commitment to explore anellovectors — a whole new class of viral shells that it claims offers the first “real alternative” to adenovirus-associated viruses, or AAV, approaches. If proved viable, that could open up a whole new frontier into diseases that are currently off limits to gene therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.